About: SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
Creator	Li, Yi Niu, Peihua Tan, Wenjie Huang, Baoying Ye, Fei Ma, Jing Peng, Feng Tan, Xin Xie, Jun Tang, Wei Zheng, Fang Zhou, Ning Xu, Yun Xie, Yuanlin Zhou, Zhiguo Zuo, Qi Tan, W Cai, Chunlin Gong, Guozhong Huang, Yaxiong Jiang, Yongfang Wang, Wenlong Xiao, Xinqiang Zhou, Yanwen Zhou, Zhiguang
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: The anti-viral effects of Novaferon, a potent antiviral protein drug on COVID-19 was evaluated in laboratory, and in a randomized, open-label, parallel group trial. METHODS: In laboratory, the inhibition of Novaferon on viral replication in cells infected with SARS-CoV-2, and on prevention of SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir were evaluated. The primary endpoint was the SARS-CoV-2 clearance rates on day 6 of treatment, and the secondary endpoint was the time to SARS-CoV-2 clearance. RESULTS: Novaferon inhibited the viral replication (EC(50) = 1.02 ng/ml), and prevented viral infection (EC(50) = 0.10 ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher viral clearance rates on day 6than Lopinavir/Ritonavir group (50.0% vs.24.1%, p = 0.0400, and 60.0% vs.24.1%, p = 0.0053). Median time to viral clearance were 6 days, 6 days, and 9 days for three groups respectively, a 3-dayreductionin both Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with Lopinavir/Ritonavir group. CONCLUSIONS: Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justified the further evaluation of Novaferon. TRIAL REGISTRATION NUMBER: number ChiCTR2000029496at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).
has issue date	2020-08-03(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.07.053
bibo:pmid	32758689
has license	no-cc
sha1sum (hex)	1b1a69877d0ed38e1c3573e8535e8667ed58c9f3
schema:url	https://doi.org/10.1016/j.ijid.2020.07.053
resource representing a document's title	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
has PubMed Central identifier	PMC7397938
has PubMed identifier	32758689
schema:publication	Int J Infect Dis
resource representing a document's body	covid:1b1a69877d0ed38e1c3573e8535e8667ed58c9f3#body_text
is schema:about of	named entity 'Please' named entity 'Randomized' named entity 'Group' named entity 'readability' named entity 'https' named entity 'cover' named entity 'Patients' named entity 'doi' named entity 'PDF file' named entity 'COVID-19' named entity 'Parallel Group' named entity 'Open-label' named entity 'SARS-CoV-2' named entity 'viral shedding' named entity 'primary endpoint' named entity 'denaturation' named entity 'WHO' named entity 'antiviral' named entity 'nucleic acids' named entity 'protein drug' named entity 'viral entry' named entity 'antiviral drugs' named entity 'WHO' named entity 'viral shedding' named entity 'adenovirus' named entity 'pneumonia' named entity 'Hunan Province' named entity 'cDNA' named entity 'nucleic acids' named entity 'China' named entity 'Chi-square test' named entity 'China.' named entity 'Lopinavir/Ritonavir' named entity 'SARS-CoV-2' named entity 'cDNA library' named entity 'nasopharyngeal swab' named entity 'Kaplan-Meier method' named entity 'protein' named entity 'protein' named entity 'internal standard' named entity 'nasopharyngeal swab' named entity 'potency' named entity 'statistically significant' named entity 'Lopinavir/Ritonavir' named entity 'assay' named entity 'Lopinavir/Ritonavir' named entity 'virus transmission' named entity 'SARS-CoV-2' named entity 'Lopinavir/Ritonavir' named entity 'naturally occurring' named entity 'homology' named entity 'RT-PCR' named entity 'Hunan' named entity 'SARS-CoV-2' named entity 'SLAN' named entity 'SARS' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software